News | February 25, 2022
Risk appetite key to innovation in pharma and biopharma
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
The newly enhanced drug development platform will help empower innovators with the fastest development timelines
Health experts of the country have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients
The drug is priced at Rs 2000 for a course of 40 tablets
The brand is now available pan-India through their distribution partner
A toll-free helpline to be set up to help doctors and patients
The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use
The product is expected to be available in a week’s time
DCGI approved the drug based on the review of clinical data
The drug will be marketed under the brand name Molnaflu
Subscribe To Our Newsletter & Stay Updated
